Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02023905 · ClinicalTrials.gov registry record · Phase 2
Everolimus With and Without Temozolomide in Adult Low Grade Glioma
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT02023905 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 27 participants.
The verdict
NCT02023905, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects, good and/or bad, everolimus (RAD001, also known as Afinitor®) alone or with temozolomide has on the patient and the patient's low-grade glioma. Everolimus is being investigated as an anticancer agent based on its potential to prevent tumor cells from growing and multiplying. Specifically, there is a protein called mTOR that we think helps many tumors to grow, and everolimus blocks the effect of mTOR. Temozolomide is also an anticancer agent that prevents tumor cells from growing and multiplying.
Interventions
- DRUG Temozolomide
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2014-03-19 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02023905
The ClinicalTrials.gov registry entry for NCT02023905 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Temozolomide is the first listed.
NCT02023905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02023905 about?
NCT02023905 is a clinical study titled "Everolimus With and Without Temozolomide in Adult Low Grade Glioma". The purpose of this study is to find out what effects, good and/or bad, everolimus (RAD001, also known as Afinitor®) alone or with temozolomide has on the patient and the patient's low-grade glioma. Everolimus is being investigated as an anticancer agent based on its potential to prevent tumor cells...
What is the current status of trial NCT02023905?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2014-03-19. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT02023905?
The interventions under investigation include: Temozolomide (DRUG), Everolimus (DRUG).
Who is sponsoring clinical trial NCT02023905?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.